FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 169 filers reported holding FATE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 9.78 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2021 | $175,000 | -37.5% | 2,949 | -8.6% | 0.01% | -30.8% |
| Q2 2021 | $280,000 | +17.2% | 3,228 | +11.4% | 0.01% | +8.3% |
| Q1 2021 | $239,000 | +184.5% | 2,898 | +35.9% | 0.01% | +140.0% |
| Q3 2020 | $84,000 | -53.3% | 2,133 | -59.2% | 0.01% | -58.3% |
| Q2 2020 | $180,000 | +78.2% | 5,234 | +14.5% | 0.01% | +50.0% |
| Q1 2020 | $101,000 | +159.0% | 4,572 | +125.3% | 0.01% | +300.0% |
| Q4 2019 | $39,000 | +85.7% | 2,029 | +46.1% | 0.00% | +100.0% |
| Q3 2019 | $21,000 | -89.8% | 1,389 | -86.3% | 0.00% | -92.9% |
| Q2 2019 | $205,000 | +310.0% | 10,108 | +257.7% | 0.01% | +250.0% |
| Q1 2019 | $50,000 | +400.0% | 2,826 | +248.5% | 0.00% | +300.0% |
| Q4 2018 | $10,000 | 0.0% | 811 | +28.1% | 0.00% | 0.0% |
| Q3 2018 | $10,000 | -100.0% | 633 | -75.5% | 0.00% | -66.7% |
| Q2 2018 | $29,325,000 | +244275.0% | 2,586 | +128.0% | 0.00% | +200.0% |
| Q1 2018 | $12,000 | +1100.0% | 1,134 | +422.6% | 0.00% | – |
| Q4 2017 | $1,000 | – | 217 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $131,006,000 | 24.77% |
| Redmile Group, LLC | 12,957,222 | $502,351,000 | 15.68% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $40,214,000 | 7.85% |
| Casdin Capital, LLC | 3,400,000 | $131,818,000 | 5.91% |
| Ally Bridge Group (NY) LLC | 181,500 | $7,037,000 | 5.22% |
| DAFNA Capital Management LLC | 500,930 | $19,421,000 | 5.06% |
| Deep Track Capital, LP | 2,000,000 | $77,540,000 | 4.97% |
| Artal Group S.A. | 2,000,000 | $77,540,000 | 3.25% |
| Tri Locum Partners LP | 190,345 | $7,380,000 | 2.88% |
| ARK Investment Management | 10,988,182 | $426,012,000 | 1.78% |